AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Livenowfox

Published November 13, 2026 · Updated November 14, 2026

US to fund new research into potential PTSD treatment for veterans | LiveNOW from FOX

Read the full story at Livenowfox

announced that the U.S. government will spend up to $4.9 million to establish a clinical trial framework testing the psychedelic drug ibogaine as a.

Post on X

Share this story

Surfaced by this Google Alert

Ibogaine